Technical Analysis for ZLDPF - Zealand Pharma A/S Ord

Grade Last Price % Change Price Change
grade B 31.54 0.29% 0.0900
ZLDPF closed up 0.29 percent on Tuesday, November 26, 2019, on 8 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up
See historical ZLDPF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 0.29%
Wide Bands Range Expansion 0.29%
Overbought Stochastic Strength 0.29%
Gapped Down Weakness 0.29%
New 52 Week Closing High Bullish -4.71%
Narrow Range Bar Range Contraction -4.71%
Older signals for ZLDPF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Biotechnology Medical Specialties RTT Diabetes Organ Systems Endocrine System Peptide Hormones Sanofi Eli Lilly And Company Recombinant Proteins Short Bowel Syndrome Treatment Of Short Bowel Syndrome Lixisenatide Boehringer Ingelheim Congenital Hyperinsulinism

Is ZLDPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.1
52 Week Low 12.1001
Average Volume 6,621
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 22.7723
10-Day Moving Average 26.8940
Average True Range 1.3904
ADX 32.17
+DI 72.6243
-DI 25.2011
Chandelier Exit (Long, 3 ATRs ) 28.9288
Chandelier Exit (Short, 3 ATRs ) 16.2713
Upper Bollinger Band 34.2961
Lower Bollinger Band 11.2485
Percent B (%b) 0.88
BandWidth 101.2089
MACD Line 4.4786
MACD Signal Line 3.5403
MACD Histogram 0.9384
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.5400
Resistance 3 (R3) 31.5400 31.5400 31.5400
Resistance 2 (R2) 31.5400 31.5400 31.5400 31.5400
Resistance 1 (R1) 31.5400 31.5400 31.5400 31.5400 31.5400
Pivot Point 31.5400 31.5400 31.5400 31.5400 31.5400
Support 1 (S1) 31.5400 31.5400 31.5400 31.5400 31.5400
Support 2 (S2) 31.5400 31.5400 31.5400 31.5400
Support 3 (S3) 31.5400 31.5400 31.5400
Support 4 (S4) 31.5400